Nordic Nanovector’s Betalutin continues to show promising efficacy and increasing Duration of Response.
Nordic Nanovector, a biotechnology company focusing on the development of novel targeted therapeutics in haematology and oncology, announces updated results of its ongoing Phase 1/2 study with Betalutin in relapsed non-Hodgkin lymphoma (NHL) patients.
Betalutin was generally well tolerated and showed a 63.2% Overall Response Rate (ORR) including 31.6% Complete Response (CR) among 21 patients with previously treated CD37+ NHL patients. This data include two additional patients whose efficacy data has become available following submission of the abstract.
Advertisement
